Biocytogen
Daxing · Founded 2008
About Biocytogen
Biocytogen is a biopharmaceutical company that provides biomedical communities with integrated solutions for antibody drug development. Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMabTM Mouse), and in vivo/in vitro preclinical validation studies, using gene editing technologies and a state-of-the-art animal facility. Biocytogen works with the world's leading pharmaceutical and biotechnology companies.
Company Facts
- Founded: 2008
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Total funding: $335.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2022)
- Ticker: hkg:02315
- Website: biocytogen.com
- Phone: 781-587-3558
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/biocytogen-114290 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.